R-Bendamustine in the treatment of nodular lymphocyte-predominant Hodgkin lymphoma

References

• Fanale M. Lymphocyte-predominant Hodgkin lymphoma: what is the optimal treatment? Hematol Am Soc Hematol Educ Program. 2013;2013:406–413.
   PubMed Web of Science ®Google Scholar
• Miettinen M, Franssila KO, Saxen E. Hodgkin’s disease, lymphocytic predominance nodular increased risk for subsequent non-Hodgkin’s lymphomas. Cancer. 1983;51:2293–2300.
   PubMed Web of Science ®Google Scholar
• Xing KH, Savage KJ. Modern management of lymphocyte-predominant Hodgkin lymphoma. Br J Haematol. 2013;161:316–329.
   PubMed Web of Science ®Google Scholar
• McKay P, Fielding P, Gallop-Evans E, et al. Guidelines for the investigation and management of nodular lymphocyte predominant Hodgkin lymphoma. Br J Haematol. 2016;172:32–43.
   PubMed Web of Science ®Google Scholar
• Advani RH, Hoppe RT. How I treat nodular lymphocyte predominant Hodgkin lymphoma. Blood. 2013;122:4182–4188.
   PubMed Web of Science ®Google Scholar
• Nogova L, Reineke T, Brillant C, et al. Lymphocyte-predominant and classical Hodgkin’s lymphoma: a comprehensive analysis from the German Hodgkin study group. J Clin Oncol. 2008;26:434–439.
   PubMed Web of Science ®Google Scholar
• Tsai HK, Mauch PM. Nodular lymphocyte-predominant Hodgkin lymphoma. Semin Radiat Oncol. 2007;17:184–189.
   PubMed Web of Science ®Google Scholar
• Unal A, Sari I, Deniz K, et al. Familial nodular lymphocyte predominant Hodgkin lymphoma: successful treatment with CHOP plus rituximab. Leuk Lymphoma. 2005;46:1613–1617.
   PubMed Web of Science ®Google Scholar
• Schulz H, Rehwald U, Morschhauser F, et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin lymphoma study group (GHSG). Blood. 2008;111:109–111.
   PubMed Web of Science ®Google Scholar
• Ekstrand BC, Lucas JB, Horwitz SM, et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood. 2003;101:4285–4289.
   PubMed Web of Science ®Google Scholar
• Lukes RJ, Butler JJ, Hicks EB. Natural history of Hodgkin’s disease as related to its pathologic picture. Cancer. 1966;19:317–344.
   Web of Science ®Google Scholar
• Xing KH, Connors JM, Lai A, et al. Advanced-stage nodular lymphocyte predominant hodgkin lymphoma compared with classical hodgkin lymphoma: a matched pair outcome analysis. Blood. 2014;123:3567–3573.
   PubMed Web of Science ®Google Scholar
• Cencini E, Fabbri A, Bocchia M. Rituximab plus ABVD in newly diagnosed nodular lymphocyte-predominant hodgkin lymphoma. Br J Haematol. 2017;176:831–833.
   PubMed Web of Science ®Google Scholar
• van Leeuwen FE, Ng AK. Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment. Hematol Am Soc Hematol Educ Program. 2016;2016:323–330.
   PubMed Web of Science ®Google Scholar
• Diehl V, Sextro M, Franklin J, et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin’s disease and lymphocyte-rich classical Hodgkin’s disease: report from the European task force on lymphoma project on lymphocyte-predominant Hodgkin’s disease. J Clin Oncol. 1999;17:776–783.
   PubMed Web of Science ®Google Scholar
• Ng AK. Review of the cardiac long-term effects of therapy for Hodgkin lymphoma. Br J Haematol. 2011;154:23–31.
   PubMed Web of Science ®Google Scholar
• Hodgson DC. Long-term toxicity of chemotherapy and radiotherapy in lymphoma survivors: optimizing treatment for individual patients. Clin Adv Hematol Oncol. 2015;13:103–112.
   PubMed Web of Science ®Google Scholar
• Ng AK. Current survivorship recommendations for patients with Hodgkin lymphoma: focus on late effects. Blood. 2014;124:3373–3379.
   PubMed Web of Science ®Google Scholar
• Fanale MA, Lai C, McLaughlin P, et al. Outcomes of nodular lymphocyte predominant hodgkin'slymphoma (NLPHL) patients treated with R-CHOP. Blood (ASH Annual Meeting Abstracts). 2010;116:2812.
   PubMed Web of Science ®Google Scholar
• Advani RH, Horning SJ, Hoppe RT, et al. Mature results of a phase II study of rituximab therapy for nodular lymphocytepredominant hodgkin lymphoma. J Clin Oncol. 2014;32:912–918.
   PubMed Web of Science ®Google Scholar
• Horn J, Kleber M, Hieke S, et al. Treatment option of bendamustine in combination with rituximab in elderly and frail patients with aggressive B-non-Hodgkin lymphoma: rational, efficacy, and tolerance. Ann Hematol. 2012;91:1579–1586.
   PubMed Web of Science ®Google Scholar
• Martin P, Barr PM, James L, et al. Long-term safety experience with bendamustine for injection in a real-world setting. Expert Opin Drug Saf. 2017;16:647–650.
   PubMed Web of Science ®Google Scholar
• Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-hodgkin lymphoma: results from a multicenter study. Cancer. 2010;116:106–114.
   PubMed Web of Science ®Google Scholar
• Penne M, Sarraf Yazdy M, Nair KS, et al. Extended follow-up of patients treated with bendamustine for lymphoid malignancies. Clin Lymphoma Myeloma Leuk. 2017;17:637–644.
   PubMed Web of Science ®Google Scholar
• King MT, Donaldson SS, Link MP, et al. Management of nodular lymphocyte predominant Hodgkin lymphoma in the modern era. Int J Radiat Oncol Biol Phys. 2015;92:67–75.
   PubMed Web of Science ®Google Scholar
• Molin D, Linderoth J, Wahlin BE. Nodular lymphocyte predominant Hodgkin lymphoma in Sweden between 2000 and 2014: an analysis of the swedish lymphoma registry. Br J Haematol. 2017;177:449–456.
   PubMed Web of Science ®Google Scholar